Global Antidepressant Drugs Market Size study, by Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, Others

Global Antidepressant Drugs Market Size study, by Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin Antagonist and Reuptake Inhibitors, Others) by Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others) and Regional Forecasts 2022-2032

Global Antidepressant Drugs Market is valued approximately USD 17 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.0% over the forecast period 2024-2032. Antidepressants are a type of medication used to treat depression, a condition that causes persistent feelings of sadness and a loss of interest in activities you once enjoyed. They can also be helpful for other conditions such as anxiety and obsessive-compulsive disorder. Additionally, a variety of disorders, including post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and generalized anxiety disorder, are treated with these medications. Chronic pain sufferers are also treated with it. Prescription antidepressants can be used alone or in combination with behavioural therapy and physical activity as a first-line treatment for depression. Furthermore, rising investment in development of Antidepressant Drugs and rising awareness of disease prevalence among people are gaining attention towards Global Antidepressant Drugs Market.


The Global Antidepressant Drugs Market is driven by the rise in awareness regarding depression, increasing prevalence of depression, and advancements in research and development activities in the healthcare sector across the globe. According to the World Health Organization (WHO), in year 2021, around 5% of the adult are diagnose with depression. Antidepressant drugs maintain balance of various hormones and chemicals in the brain. Moreover, rising prevalence of life-threatening diseases such as obsessive-compulsive disorder, major depressive disorder generalized anxiety disorder is driving the marker growth. Moreover, rise in geriatric population and, increase in number of approvals for the development of antidepressant drugs is creating new opportunities to the market. However, side effects associated with drug and strict regulatory compliance is going to impede the overall demand for the market during the forecast period 2024-2032.

The key regions considered for the Global Antidepressant Drugs market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the largest regional market in terms of revenue owing to rising prevalence of depression disorder, increasing number of drug approval, presence of key market players, and rise in initiatives for the development and investment in R&D activities in the healthcare sector in region. However, Asia-Pacific is expected to register fastest growth owing to factors such as increase in prevalence of mental disorders, rise in awareness regarding depression, growth in health care expenditures, and increase in number of clinical trials are some factors which are expected to develop the region at the fastest rate over the forecast period 2024-2032.

Major market player included in this report are:
Alkermes Plc
AbbVie Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline, Inc.
H. Lundbeck A/S
Merck KGAA
Pfizer Inc.
Teva Pharmaceutical Industries Ltd. (Actavis Generics)
Takeda Pharmaceutical Limited Company

The detailed segments and sub-segment of the market are explained below:

By Product
Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Serotonin Norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors
Serotonin Antagonist and Reuptake Inhibitors
Others

By Depressive Disorders
Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.